Bengaluru, India, 17 February 2026: Cambridge Cognition Holdings plc ("Cambridge Cognition") (AIM: COG), the neuroscience technology company specialising in digital cognitive assessments, and Ivory, a venture-backed brain health company headquartered in India, announce an agreement for the commercialisation of CANTAB Pathway™ across the healthcare and consumer health markets in India.

Highlights

• Ivory will deploy CANTAB Pathway™ across both professional healthcare and consumer health segments in India

• Of India’s population of approximately 1.47 billion, estimates indicate that 138 million people are aged over 60, and as many as 34 million may be living with mild or major cognitive impairment

• India’s middle and affluent class, estimated to be 90-190 million people, is believed to have an increasing interest in longevity, healthspan, and access to high-quality healthcare  

This partnership represents an important strategic step in Cambridge Cognition’s expansion into high-growth international healthcare and consumer markets, leveraging Ivory’s rapidly scaling brain health platform and distribution network. 

India represents a significant growth opportunity with a population of approximately 1.47 billion.  Recent research estimated that among India’s 138 million people aged over 60, as many as 34 million may be living with mild or major cognitive impairment (Gross et al., PLOS One, LASI-DAD study).

Rob Baker, Chief Executive Officer - Cambridge Cognition, said, “India represents a major opportunity, with a significant unmet need for earlier identification of cognitive impairment.  As health-conscious, tech-enabled populations grow, demand for proactive brain health tools is increasing rapidly.

We believe the Ivory team shares our passion and energy to make a difference and has made impressive progress across both consumer and professional healthcare markets.  We are excited to partner with them to expand access to CANTAB Pathway™ in India.”

Ivory recently published India’s first-of-its-kind Brain Health Report, providing new insights into the country’s cognitive wellbeing landscape.  Multiple studies suggest that up to 90% of cognitive impairment remains underdiagnosed, highlighting a substantial unmet need for scalable early screening solutions.  

With no definitive cure for neurodegenerative conditions like dementia, prevention and early identification are increasingly critical.  Ivory’s mission is to shift the focus from late-stage diagnosis to proactive brain health management through neuroscience-based digital assessments, enabling individuals to take action before symptoms escalate.  

Issac John, Chief Executive Officer - Ivory, said, “Our founding scientists have known and used CANTAB for many years.  We appreciate the strong scientific pedigree of the assessments based on thousands of clinical peer-reviewed papers.  The Cambridge Cognition team have built CANTAB Pathway™ to be exactly the product we need to add to our offering to enable us to pursue our mission of shifting the focus from late-stage diagnosis to proactive brain health solutions.”

India has an expanding middle and affluent class, with an estimated 90-190 million people for whom longevity, healthspan, and access to high-quality healthcare are growing priorities.  In parallel, younger urban populations are increasingly tech-enabled and motivated to manage their health through monitoring and lifestyle choices. 

Dr. Sumiti Saharan, Chief Scientific Officer, Ivory, said “Early cognitive screening is one of the most powerful ways to change trajectories in neurodegenerative conditions, where intervention often begins only after cognitive decline has already advanced.  In India, under diagnosis of cognitive impairment remains a significant gap.  Scalable, validated digital tools such as CANTAB Pathway™ offer an opportunity to standardise assessment, enable earlier identification and empower clinicians to intervene at a stage when it can make the greatest difference.”

Dr. Anoop Amarnath, Geriatrician and Clinical Advisor to Ivory, said: “In clinical practice, we often encounter patients when cognitive impairment has already progressed to a functionally significant stage. The integration of a gold-standard tool such as the CANTAB Pathway™ assessment enhances diagnostic confidence and supports longitudinal tracking. Its availability in multiple Indian languages will further strengthen the reliability of assessment across diverse populations.”

This strategic partnership between Cambridge Cognition and Ivory offers high accuracy, low burden of administration and real-time results that are essential to improving early identification of cognitive impairment and supporting brain health at scale. 

Under this agreement, Ivory intends to deploy CANTAB Pathway™ at scale across both professional healthcare and consumer health segments in India, leveraging its established and growing clinical network, consumer-facing platform, and partnerships across hospitals, clinics, and diagnostic and health-tech ecosystems to expand access to early cognitive screening.  These flagship assessments are currently available in English and multiple languages including Hindi, Tamil, Telugu, Bengali and Kannada, with further language expansion planned.